Talphera Q2 FY26 net loss widens to $4.31 million; operating expenses rise to $3.92 million

Reuters2026/08/12 20:08

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Talphera posted a GAAP net loss attributable to common shareholders of USD 4.3 million, or USD 0.06 per share, in Q2 2026.
Combined R&D and SG&A expenses rose 5.41% to USD 3.9 million, driven by higher Niyad development costs on increased enrollment.
Cash and investments were USD 17.1 million at June 30, 2026.
NEPHRO CRRT study of nafamostat reached 75% enrollment; completion remains expected by year-end, with all target sites activated.
Draft 2026 KDIGO guidelines cited nafamostat as an acceptable CRRT anticoagulant; market research pegs 2027 U.S. CRRT procedures at 200,000.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Talphera Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202608121605PR_NEWS_USPR_____SF24274) on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Talphera Q2 FY26 net loss widens to $4.31 million; operating expenses rise to $3.92 million

You may also like

Crypto prices